1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global HIV/AIDS Diagnostics Market
2.2. Global HIV/AIDS Diagnostics Market, By Product, 2023 (US$ Million)
2.3. Global HIV/AIDS Diagnostics Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. HIV/AIDS Diagnostics Market: Competitive Analysis
3.1. Market Positioning of Key HIV/AIDS Diagnostics Market Vendors
3.2. Strategies Adopted by HIV/AIDS Diagnostics Market Vendors
3.3. Key Industry Strategies
4. HIV/AIDS Diagnostics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global HIV/AIDS Diagnostics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Antibody Tests
5.3.1.1. HIV-1 Screening Tests
5.3.1.2. ELISA
5.3.1.3. Rapid Tests
5.3.1.4. Home Access Dried Blood Spots
5.3.2. HIV-1 Antibody Confirmatory Tests
5.3.2.1. Western Blot Tests
5.3.2.2. Indirect Immunofluorescence Assays (IFA)
5.3.2.3. Line Immunoassays
5.3.2.4. Radio-Immunoprecipitation Assays
5.3.3. Viral Identification testing
5.3.3.1. P24 Antigen
5.3.3.2. Qualitative PCR Test
5.3.3.3. Viral Culture
5.3.4. Viral Load Tests
5.3.5. CD4 Testing
5.3.6. Early Infant Diagnosticss


6. North America HIV/AIDS Diagnostics Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
6.3.HIV/AIDS Diagnostics Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)

7. UK and European Union HIV/AIDS Diagnostics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.HIV/AIDS Diagnostics Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)

8. Asia Pacific HIV/AIDS Diagnostics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.HIV/AIDS Diagnostics Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)

9. Latin America HIV/AIDS Diagnostics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
9.3.HIV/AIDS Diagnostics Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)

10. Middle East and Africa HIV/AIDS Diagnostics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
10.3.HIV/AIDS Diagnostics Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. HIV/AIDS Diagnostics Market: By Product, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Abbvie Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Alere Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Apogee Flow Systems
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Beckman Coulter, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Becton, Dickinson & Company
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. BD Biosciences
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Bio-Rad Laboratories
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. BioMerieux
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Bristol-Myers Squibb
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Cepheid
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Chembio Diagnostics Systems
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Daktari Diagnosticss
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Gilead Sciences
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Hologic Inc.
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives
11.16. Merch & Co. Inc
11.16.1. Company Overview
11.16.2. Financial Performance
11.16.3. Product Portfolio
11.16.4. Strategic Initiatives
11.17. Mylan Inc
11.17.1. Company Overview
11.17.2. Financial Performance
11.17.3. Product Portfolio
11.17.4. Strategic Initiatives
11.18. Janssen Therapeutics
11.18.1. Company Overview
11.18.2. Financial Performance
11.18.3. Product Portfolio
11.18.4. Strategic Initiatives